We have shown previously that the deletion of PTP1B or PTPN2 in T cells can enhance T cell activation and cytotoxicity in vitro by promoting TCR and/or cytokine signaling, whereas in vivo the deletion of PTPN2 or PTP1B in T cells can markedly enhance anti-tumor immunity11,14. The gene discussed is PTPN1; the disease is neoplasm.